General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-04-03 | 2023-12 | -0.57 | N/A | N/A | N/A |
2023-11-07 | 2023-09 | -0.69 | -0.66 | 0.03 | 4.35% |
2023-08-08 | 2023-06 | -0.72 | -0.67 | 0.05 | 6.94% |
2023-05-09 | 2023-03 | -0.54 | 0.21 | 0.75 | 138.89% |
2023-03-29 | 2022-12 | -0.45 | 0.38 | 0.83 | 184.44% |
2022-11-07 | 2022-09 | -1.28 | -0.92 | 0.36 | 28.13% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-16 | Cantor Fitzgerald | Upgrade | Neutral | |
2023-09-05 | HSBC | Upgrade | Buy | |
2023-07-18 | B of A Securities | Upgrade | Neutral | Buy |
2023-07-10 | Morgan Stanley | Upgrade | Underweight | Underweight |
2023-05-31 | Barclays | Upgrade | Equal-Weight | Overweight |
2023-04-27 | JP Morgan | Upgrade | Overweight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-06-15 | AGWUNOBI JOHN O | Director | 26.46K | Stock Award(Grant) |
2024-02-29 | COLVIN RICHARD A | Officer | 118.37K | Sale |
2024-03-03 | KLIMA THOMAS J | Chief Operating Officer | 124.84K | Sale |
2023-12-05 | KRAWTSCHUK CHRISTOPHER CPA | Chief Financial Officer | 45.47K | Sale |
2023-06-15 | LEIDERMAN ELISABETH M.D. | Director | 22.26K | Stock Award(Grant) |
2023-06-15 | LESCHLY NICK | Director | 459.64K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | State Street Corporation | 16.36M | 53.82M | 15.29% |
2023-06-29 | Blackrock Inc. | 8.79M | 28.93M | 8.22% |
2023-06-29 | Tang Capital Management, LLC | 7.38M | 24.29M | 6.90% |
2023-06-29 | Pfm Health Sciences, Lp | 7.29M | 23.97M | 6.81% |
2023-06-29 | Vanguard Group Inc | 5.57M | 18.33M | 5.21% |
2023-06-29 | Granahan Investment Management LLC | 4.86M | 15.98M | 4.54% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-08-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 13.88M | 52.34M | 12.98% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 3.39M | 11.15M | 3.17% |
2023-08-30 | iShares Russell 2000 ETF | 2.48M | 9.36M | 2.32% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.48M | 4.86M | 1.38% |
2023-09-29 | Direxion Shares ETF Tr-Direxion Daily S&P Biotech Bull 3x Sh | 1.32M | 4.00M | 1.23% |
2023-08-30 | iShares Russell 2000 Value ETF | 987.26K | 3.72M | 0.92% |
Split | Date |
---|---|
1544 : 1000 | 2021-11-05 |
It’s a Penny stock with a .50 downside here
The bloodbath continues without end, there must be something we are not being told
Options traders dream here
The problem is that the management is so stupid they probably don’t know what to do. Great science horrible management
.80 is bottom but it’s setting up for reverse here if they are smart and choke the shorts
The Motley Fool published a good piece on $BLUE recently. Basically saying its very high risk and very high reward if they are able to pull of threading the needle. They have a short runway and most of the stars have to align from a financial resource place and business take off. That is pretty much the reality of it. Risk or count your losses. I think the “Fraud” talk and negative bitching is coming from inexperienced investors looking for easy money. There isn’t any easy money in the life of a long term investor, just wins and losses. Hopefully we all pick more winners than losers. I am holding on BLUE hoping for a series of positive actions and market responses. Now turning my head to $TNYA, $EYPT, $RYTM, $DERM, $GANX, $HARP, and a big position in $SAVA. -
The only hope is selling the company NOW or we bleed to death slowly and die in a year.
About to blastoff, it’s up .01 in the pre
Could hit .50
I’m afraid of the Q4 numbers actually
I hopevAlina Habba is not lead counsel
This is all about the court mess
The market doesn’t care about science or even the business they only care about share price and this one’s going down
The support is at .80 and the selloff will test it. Thank God it’s not tax loss season because every stock has a point of absurdity
At least it was a hell of a run to the lucky ones
The days of biotech speculation like the past 30+ years appears to be over and stock gains now will be driven by earnings. The lofty multiples finally reflect reality. The only speculation left is in acquisitions and large pharma will wait till the end of a stock collapse to see if they can buy drugs out of BK